124-Iodine-cG250 (124I-cG250)

DRUG2 trials

Sponsors

Ludwig Institute for Cancer Research, Heidelberg Pharma AG

Conditions

Cancer of KidneyClear Cell Renal Cell CarcinomaKidney CancerNeoplasms, KidneyRenal CancerRenal Cell CarcinomaRenal Cell Carcinoma (RCC)Renal Neoplasms

Phase 1

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

CompletedNCT00199888

Ludwig Institute for Cancer ResearchCancer of Kidney, Clear Cell Renal Cell Carcinoma, Kidney Cancer +4

Start: 2005-06-30End: 2009-05-29Updated: 2022-10-10

Phase 3

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

CompletedNCT00606632

Heidelberg Pharma AGKidney Cancer, Renal Cell Carcinoma

Start: 2008-03-31End: 2009-12-31Updated: 2018-10-02

Related Papers

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

2007-04-01240 citations